Clinical trials
Phase 3 Leukemia, Lymphocytic, Chronic, B-Cell trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Active, not recruiting | 9 |
| Recruiting | 6 |
| Terminated | 5 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 5 |
| Gilead Sciences | 4 |
| Hoffmann-La Roche | 4 |
| Pharmacyclics LLC. | 4 |
| Acerta Pharma BV | 3 |
| Janssen Research & Development, LLC | 3 |
| Loxo Oncology, Inc. | 3 |
| AbbVie | 2 |
| BeOne Medicines | 2 |
| BeiGene | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 43 |
| Lymphoma, Non-Hodgkin | 8 |
| Leukemia | 7 |
| Recurrence | 6 |
| Lymphoma | 5 |
| Lymphoma, Follicular | 5 |
| Multiple Myeloma | 5 |
| Neoplasms | 5 |
| Burkitt Lymphoma | 4 |
| Leukemia, Myeloid, Acute | 4 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.